Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.
Roche (RHHBY) announced new data highlighting the potential of Lunsumio, mosunetuzumab, in earlier treatment lines for people ...
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback